CervoMed Inc. (CRVO) has received a notice of allowance from the United States Patent and Trademark Office related to a new patent protecting its drug candidate, Neflamapimod, for the treatment of dementia with Lewy bodies (DLB) in patients with no substantial Alzheimer's disease-like tau pathology, also known as "pure DLB".
Why it matters?
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com